keyword
MENU ▼
Read by QxMD icon Read
search

adalimumab level

keyword
https://www.readbyqxmd.com/read/29771301/anti-tnf-levels-in-cord-blood-at-birth-are-associated-with-anti-tnf-type
#1
Shannon L Kanis, Alison de Lima, Cokkie van der Ent, Dimitris Rizopoulos, C Janneke van der Woude
Background and Aims: Pregnancy guidelines for women with Inflammatory Bowel Disease (IBD) provide recommendations regarding anti-TNF cessation during pregnancy, in order to limit fetal exposure. Although infliximab (IFX) leads to higher anti-TNF concentrations in cord blood than adalimumab (ADA), recommendations are similar. We aimed to demonstrate the effect of anti-TNF cessation during pregnancy on fetal exposure, for IFX and ADA separately. Methods: We conducted a prospective single center cohort study...
May 15, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29732713/risk-factors-and-biomarkers-for-the-occurrence-of-uveitis-in-jia-data-from-the-inception-cohort-of-newly-diagnosed-patients-with-juvenile-idiopathic-arthritis-icon-jia-study
#2
Christoph Tappeiner, Jens Klotsche, Claudia Sengler, Martina Niewerth, Ina Liedmann, Karoline Walscheid, Miha Lavric, Dirk Foell, Kirsten Minden, Arnd Heiligenhaus
PURPOSE: To analyze the prognostic value of demographic, clinical, and therapeutic factors and laboratory biomarkers, and to assess their role in predicting uveitis occurrence in patients with JIA. METHODS: Patients with JIA were enrolled within the first year after JIA diagnosis. Demographic and clinical parameters were documented. Serum samples were collected at study enrollment, at 3-month follow-up visits within the first year, and then 6-monthly. A multivariable Cox regression analysis was performed to evaluate the impact of demographic, clinical, laboratory, and therapeutic parameters on uveitis onset...
May 6, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29731461/-diagnosis-and-treatment-of-rheumatoid-arthritis-toward-the-best-practice-the-best-practice-for-tnf-inhibitors
#3
Hideto Kameda
As of February 2018, 5 originator TNF inhibitors(infliximab, etanercept, adalimumab, golimumab and certolizumab pegol)and biosimilar agents of infliximab and etanercept are available for rheumatoid arthritis(RA)in Japan. The effectiveness of TNF inhibitors considerably improves with concomitant methotrexate regardless of their immunogenicity. The Japan College of Rheumatology guideline for TNF inhibitor use in RA has been updated in March 2017 according to recent evidences. During the remission induction phase, maintenance of drug trough level above effective blood concentration is paramount, while the tapering and withdrawal of TNF inhibitors may be considered after achieving sustained remission...
2018: Clinical Calcium
https://www.readbyqxmd.com/read/29671190/predictors-of-sustained-clinical-response-in-patients-with-beh%C3%A3-et-s-disease-related-uveitis-treated-with-infliximab-and-adalimumab
#4
Claudia Fabiani, Antonio Vitale, Donato Rigante, Giacomo Emmi, Giuseppe Lopalco, Jurgen Sota, Lorenzo Vannozzi, Gerardo di Scala, Silvana Guerriero, Ida Orlando, Rossella Franceschini, Marco Capozzoli, Bruno Frediani, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Luca Cantarini
To identify clinical variables capable of predicting long-term treatment duration of TNF-α inhibition in patients with Behçet's disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients treated with the tumor necrosis factor (TNF)-α blockers infliximab and adalimumab. Patients still continuing TNF-α inhibitors at 48-month follow-up visits were classified as long-term responders and were statistically compared to patients discontinuing treatment before the 48-month visit...
April 18, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29668893/therapeutic-drug-monitoring-guides-the-management-of-crohn-s-patients-with-secondary-loss-of-response-to-adalimumab
#5
Sophie Restellini, Che-Yung Chao, Peter L Lakatos, Achuthan Aruljothy, Haya Aziz, Omar Kherad, Alain Bitton, Gary Wild, Waqqas Afif, Talat Bessissow
Background: Managing loss of response (LOR) in Crohn's disase (CD) patients remains challenging. Compelling evidence supports therapeutic drug monitoring (TDM) to guide management in patients on infliximab, but data for other biologics are less robust. We aimed to asses if empiric dose escalation led to improved clinical outcome in addition to TDM-guided optimization in CD patients with LOR to adalimumab (ADA). Methods: Retrospective chart review of patients followed between 2014 and 2016 at McGill IBD Center with index TDM for LOR to ADA was performed...
April 13, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29667098/treatment-patterns-among-patients-with-rheumatic-disease-rheumatoid-arthritis-ra-ankylosing-spondylitis-as-psoriatic-arthritis-psa-and-undifferentiated-arthritis-una-treated-with-subcutaneous-tnf-inhibitors
#6
Kathleen Tymms, Geoff Littlejohn, Hedley Griffiths, Julien de Jager, Paul Bird, Fred Joshua, Peter Nash, Malcolm Handel, Hamish McManus, Belinda E Butcher, Peter Youssef
The aim was to describe the real-world treatment persistence of subcutaneous TNF inhibitors (TNFi) for patients with inflammatory rheumatic disease newly initiating treatment with biologic disease-modifying antirheumatic drugs (bDMARD). This was a retrospective cohort study that extracted data for new users of TNFi between 1 August 2010 and 31 August 2016 from the Australian Optimising Patient outcome in Australian RheumatoLogy (OPAL) registry. Patients were 1:1 propensity-score matched with golimumab based on their age, sex, year of index, C-reactive protein level, baseline treatment combination and disease...
June 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29657832/predictive-value-of-serum-calprotectin-s100a8-a9-for-clinical-response-after-starting-or-tapering-anti-tnf-treatment-in-patients-with-rheumatoid-arthritis
#7
Lieke Tweehuysen, Nathan den Broeder, Noortje van Herwaarden, Leo A B Joosten, Peter L van Lent, Thomas Vogl, Frank H J van den Hoogen, Rogier M Thurlings, Alfons A den Broeder
Objectives: Calprotectin (S100A8/A9) has been correlated with disease activity in rheumatoid arthritis (RA). The aim of this study was to investigate the predictive value of serum calprotectin for clinical response after starting and tapering anti-tumour necrosis factor treatment in RA. Methods: Serum samples and clinical outcomes were derived from two longitudinal RA studies.At baseline (starting or tapering of adalimumab or etanercept), calprotectin levels were determined by ELISA...
2018: RMD Open
https://www.readbyqxmd.com/read/29624580/estimating-the-response-and-economic-burden-of-rheumatoid-arthritis-patients-treated-with-biologic-disease-modifying-antirheumatic-drugs-in-taiwan-using-the-national-health-insurance-research-database-nhird
#8
Qiang Shi, Ko-Jen Li, Tamas Treuer, Bruce C M Wang, Carol L Gaich, Chien-Hsun Lee, Wen-Shuo Wu, Wesley Furnback, Chao-Hsiun Tang
BACKGROUND: Previous studies in Taiwan utilizing the Taiwan's National Health Insurance Database (NHIRD) have estimated the direct healthcare costs of RA patients, but they have not focused on patients on bDMARDs, or considered patients' response to therapy. OBJECTIVES: The objective of this study was to estimate the rate of inadequate response for patients newly treated with biologic disease-modifying antirheumatic drugs (bDMARDs) as well as their costs and resource use...
2018: PloS One
https://www.readbyqxmd.com/read/29623105/subtherapeutic-concentrations-of-infliximab-and-adalimumab-are-associated-with-increased-disease-activity-in-crohn-s-disease
#9
Arne Carlsen, Roald Omdal, Kristian Øgreid Leitao, Kjetil Isaksen, Anne Kristine Hetta, Lars Normann Karlsen, Lars Aabakken, Nils Bolstad, David Warren, Knut E A Lundin, Tore Grimstad
Background: Low anti-tumor necrosis factor α (TNFα) serum concentrations may result in lack of treatment response in patients with inflammatory bowel disease. We determined the anti-TNFα drug concentrations in patients with inflammatory bowel disease and investigated whether or not subtherapeutic drug concentrations were associated with increased levels of disease activity. Methods: In a single-center cross-sectional study, we included patients with ulcerative colitis or Crohn's disease who were receiving infliximab or adalimumab maintenance therapy...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29608486/simultaneous-quantification-of-adalimumab-and-infliximab-in-human-plasma-by-liquid-chromatography-tandem-mass-spectrometry
#10
Jean-François Jourdil, Benjamin Némoz, Elodie Gautier-Veyret, Charlotte Romero, Françoise Stanke-Labesque
BACKGROUND: Adalimumab (ADA) and infliximab (IFX) are therapeutic monoclonal antibodies (TMabs) targeting tumor necrosis factor-alpha (TNFα). They are used to treat inflammatory diseases. Clinical trials have suggested that therapeutic drug monitoring for ADA or IFX could improve treatment response and cost-effectiveness. However, ADA and IFX were quantified by ELISA in all these studies, and the discrepancies between the results obtained raise questions about their reliability.We describe here the validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of ADA and IFX in human samples...
March 30, 2018: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29605872/biological-therapy-downregulates-the-heterodimer-s100a8-a9-calprotectin-expression-in-psoriatic-patients
#11
F D'Amico, M Granata, E Skarmoutsou, C Trovato, G Lovero, P Gangemi, V Longo, M Pettinato, M C Mazzarino
The pathophysiology of psoriasis is very complex and involves an interplay between immune cells and keratinocytes. The keratinocyte production of calprotectin (S100A8/A9), induced by the inflammatory psoriatic milieu, may be involved in initiating immune cell invasion, as well as in propagating inflammation. However, the exact role of calprotectin in psoriasis remains unclear. Therapeutic approaches utilizing adalimumab, etanercept and ustekinumab are widely used in psoriatic treatment, but their anti-inflammatory mechanisms are not fully understood...
March 31, 2018: Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.]
https://www.readbyqxmd.com/read/29564674/interactions-between-thiopurine-metabolites-adalimumab-and-antibodies-against-adalimumab-in-previously-infliximab-treated-patients-with-inflammatory-bowel-disease
#12
Rikke B Holmstrøm, Ditte V Mogensen, Jørn Brynskov, Mark A Ainsworth, Jacob Nersting, Kjeld Schmiegelow, Casper Steenholdt
BACKGROUND: Interactions between thiopurines and infliximab presumably contribute to superior effect of infliximab-thiopurine combination therapy in patients with inflammatory bowel disease (IBD). We examined whether principal cytotoxic thiopurine metabolites influence adalimumab (ADL) and anti-ADL antibodies (Abs). METHODS: Ninety-eight IBD patients previously treated with infliximab (96%) in whom trough ADL and anti-ADL Abs had been assessed as part of their clinical care were included...
March 21, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29563546/preclinical-development-of-a-novel-orally-administered-anti-tumour-necrosis-factor-domain-antibody-for-the-treatment-of-inflammatory-bowel-disease
#13
J Scott Crowe, Kevin J Roberts, Timothy M Carlton, Luana Maggiore, Marion F Cubitt, Simon Clare, Katherine Harcourt, Jill Reckless, Thomas T MacDonald, Keith P Ray, Anna Vossenkämper, Michael R West
TNFα is an important cytokine in inflammatory bowel disease. V565 is a novel anti-TNFα domain antibody developed for oral administration in IBD patients, derived from a llama domain antibody and engineered to enhance intestinal protease resistance. V565 activity was evaluated in TNFα-TNFα receptor-binding ELISAs as well as TNFα responsive cellular assays and demonstrated neutralisation of both soluble and membrane TNFα with potencies similar to those of adalimumab. Although sensitive to pepsin, V565 retained activity after lengthy incubations with trypsin, chymotrypsin, and pancreatin, as well as mouse small intestinal and human ileal and faecal supernatants...
March 21, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29562373/efficacy-of-switching-to-infliximab-in-patients-with-crohn-s-disease-with-loss-of-response-to-adalimumab
#14
H Peeters, E Louis, F Baert, O Dewit, J C Coche, M Ferrante, G Lambrecht, A Colard, A Van Gossum, P Bossuyt, T Moreels, B Vander Cruyssen, A Gils, M De Vos
BACKGROUND AND STUDY AIMS: Anti-TNF monoclonal antibodies are a cornerstone in the treatment of Crohn's disease. Prospective data on switching from the subcutaneous and human adalimumab (ADM) to the intravenous and chimeric infliximab (IFX) are scarce. PATIENTS AND METHODS: In this prospective, observational, multicentre cohort study we included 21 patients with loss of response to ADM despite at least 4 consecutive weekly injections. Clinical response (CDAI drop≥70 points) and remission (CDAI≤150) were assessed after switching from ADM to IFX after 10 weeks, 6 and 12 months...
January 2018: Acta Gastro-enterologica Belgica
https://www.readbyqxmd.com/read/29552370/effect-of-adalimumab-on-refractory-arthritis-in-juvenile-idiopathic-inflammatory-myopathy-with-anti-mda5-autoantibody
#15
Takako Miyamae, Takuma Hara, Aki Hanaya, Yumi Tani, Takayuki Kishi, Hisashi Yamanaka
A 10-year-old girl manifested persistent fever, skin rash, leg pain, fatigue, and joint pain. Based on muscle weakness, elevated muscle-derived enzymes, magnetic resonance imaging, and skin biopsy results, the diagnosis was juvenile idiopathic inflammatory myopathies (JIIM). Chest CT was normal; the anti-melanoma differentiation-associated protein-5 (anti-MDA5) autoantibody was positive. Initial manifestations subsided after prednisolone (PSL) and methotrexate treatment. After the PSL dosage was decreased, the patient presented with metacarpophalangeal (MCP) joint pain and swelling in both index fingers, synovial fluid, and signals on power Doppler ultrasound...
2018: Case Reports in Rheumatology
https://www.readbyqxmd.com/read/29541795/the-role-of-lymphotoxin-%C3%AE-in-rheumatoid-arthritis
#16
REVIEW
Tomohiro Hirose, Yuri Fukuma, Ayumu Takeshita, Keiichiro Nishida
BACKGROUND: The role of tumor necrosis factor (TNF) in the inflammatory response in rheumatoid arthritis (RA) is well established, whereas less is known about the role of TNF's close homolog, lymphotoxin alpha (LTα). FINDINGS: Increased levels of LTα are found in the serum and synovial tissue of patients with RA, and in vitro studies found that LTα-induced proliferation of RA fibroblast-like synoviocytes was at a similar level to TNF. These findings support the idea that anti-LTα treatment could be beneficial in patients with RA, but pateclizumab, an anti-LTα antibody, was not as efficacious as the anti-TNF agent adalimumab in reducing symptoms of RA in a head-to-head study, suggesting that anti-LTα therapies might not represent a valid alternative treatment option in patients with RA...
March 14, 2018: Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.]
https://www.readbyqxmd.com/read/29531640/blood-glucose-changes-surrounding-initiation-of-tumor-necrosis-factor-inhibitors-and-conventional-disease-modifying-anti-rheumatic-drugs-in-veterans-with-rheumatoid-arthritis
#17
Patrick R Wood, Evan Manning, Joshua F Baker, Bryant England, Lisa Davis, Grant W Cannon, Ted R Mikuls, Liron Caplan
AIM: To determine the scope of acute hypoglycemic effects for certain anti-rheumatic medications in a large retrospective observational study. METHODS: Patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry were selected who, during follow-up, initiated treatment with tumor necrosis factor inhibitors (TNFi's, including etanercept, adalimumab, infliximab, golimumab, or certolizumab), prednisone, or conventional disease-modifying anti-rheumatic drugs (DMARDs), and for whom proximate random blood glucose (RBG) measurements were available within a window 2-wk prior to, and 6 mo following, medication initiation...
February 15, 2018: World Journal of Diabetes
https://www.readbyqxmd.com/read/29518978/structural-biology-of-the-tnf%C3%AE-antagonists-used-in-the-treatment-of-rheumatoid-arthritis
#18
REVIEW
Heejin Lim, Sang Hyung Lee, Hyun Tae Lee, Jee Un Lee, Ji Young Son, Woori Shin, Yong-Seok Heo
The binding of the tumor necrosis factor α (TNFα) to its cognate receptor initiates many immune and inflammatory processes. The drugs, etanercept (Enbrel® ), infliximab (Remicade® ), adalimumab (Humira® ), certolizumab-pegol (Cimzia® ), and golimumab (Simponi® ), are anti-TNFα agents. These drugs block TNFα from interacting with its receptors and have enabled the development of breakthrough therapies for the treatment of several autoimmune inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis...
March 7, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29490959/design-of-a-phase-iv-randomised-double-blind-placebo-controlled-trial-assessing-the-im-p-act-of-r-esidual-inflammation-detected-via-imaging-t-e-chniques-d-rug-levels-and-patient-characteristics-on-the-outcome-of-dose-taper-i-ng-of-adalimumab-in-c-linical-remission
#19
Paul Emery, Gerd R Burmester, Esperanza Naredo, Yijie Zhou, Maja Hojnik, Philip G Conaghan
INTRODUCTION: The current American College of Rheumatology and European League Against Rheumatism treatment recommendations advise tapering biological disease-modifying antirheumatic drug (bDMARD) therapy in patients with rheumatoid arthritis (RA) who achieve stable clinical remission while receiving bDMARDs. However, not all patients maintain remission or low disease activity after tapering or discontinuation of bDMARDs. The aim of the Im P act of R esidual Inflammation Detected via Imaging T E chniques, D rug Levels and Patient Characteristics on the Outcome of Dose Taper I ng of Adalimumab in C linical Remission Rheumatoid Ar T hritis ( RA ) study, or PREDICTRA, is to generate data on patient and disease characteristics that may predict the clinical course of a fixed dose-tapering regimen with the bDMARD adalimumab...
February 28, 2018: BMJ Open
https://www.readbyqxmd.com/read/29479473/response-to-baricitinib-therapy-in-patients-with-rheumatoid-arthritis-with-inadequate-response-to-csdmards-as-a-function-of-baseline-characteristics
#20
Joel M Kremer, Michael Schiff, David Muram, Jinglin Zhong, Jahangir Alam, Mark C Genovese
Objective: We analysed the effects of baseline characteristics on the safety and efficacy of baricitinib in patients with rheumatoid arthritis (RA) with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) from two phase III trials. Methods: In RA-BEAM (NCT01710358), patients with inadequate response to methotrexate were randomised to placebo, baricitinib 4 mg or adalimumab 40 mg. RA-BUILD (NCT01721057) patients had inadequate response to ≥1 csDMARDs and were randomised to either placebo or once-daily baricitinib (2 or 4 mg)...
2018: RMD Open
keyword
keyword
53794
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"